Clinical Trials Logo

Hyperlipidemia clinical trials

View clinical trials related to Hyperlipidemia.

Filter by:

NCT ID: NCT06422650 Recruiting - Hyperlipidemia Clinical Trials

Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia

Start date: August 24, 2023
Phase: Phase 2
Study type: Interventional

This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of Nigella Sativa in 84 Hyperlipidaemic patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either Nigella Sativa 500 mg capsule daily or placebo capsule identical to Nigella Sativa twice daily for 8 weeks. Evaluation of lipid profile, SGPT, S.Creatinine will be before and after 8 weeks of intervention. Nigella Sativa related adverse events will be identified. Study outcome will establish safety and efficacy of Nigella Sativa in atorvastatin treated hyperlipidaemic patients

NCT ID: NCT06224296 Not yet recruiting - Hyperlipidemia Clinical Trials

The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood. It's also postulated that DFPP could boost immune cells through removing certain inflammatory cytokines and blood lipids.

NCT ID: NCT06166121 Recruiting - Hyperlipidemia Clinical Trials

Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules

Start date: September 20, 2023
Phase: N/A
Study type: Interventional

This study focuses on PWV as the main outcome, aiming to evaluate the efficacy and safety of ShenJu in treating patients with hyperlipidemia combined with carotid atherosclerosis, and provide a basis for traditional Chinese medicine treatment of hyperlipidemia combined with carotid atherosclerosis.

NCT ID: NCT06041165 Recruiting - Hyperlipidemia Clinical Trials

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401

Start date: August 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single-dose of JS401 in healthy volunteers with normal or mildly elevated triglycerides.

NCT ID: NCT06022575 Recruiting - Hyperlipidemia Clinical Trials

Telehealth Integrated Care Model in Patients With Cardiometabolic Disease

Start date: June 20, 2023
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. The result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.

NCT ID: NCT06002893 Completed - Hyperlipidemia Clinical Trials

The Antihypercholestrolemic Effect of a Combined Nutritional Supplementation of Standardized Extracts of Amla, Walnut, Red Yeast Rice and Olive

Start date: March 19, 2020
Phase: N/A
Study type: Interventional

Nutraceutical lipid-lowering interventions are becoming increasingly popular, particularly among patients who are intolerant or refractory to prescription statins, or who desire alternative non-conventional pharmacological treatment to manage their dyslipidaemia, whether they previously experienced statin intolerance or not. A growing body of preclinical and clinical evidence suggest that the amla (Emblica officinalis) red yeast rice (RYR), olive and walnut leaf extracts posses consideable hpolipidaemic pharmacological effects.

NCT ID: NCT05990595 Recruiting - Type 2 Diabetes Clinical Trials

Evaluation of Health Effects of Adlay on Hyperlipidemia and Hyperglycemia Control

ADL
Start date: July 7, 2023
Phase: N/A
Study type: Interventional

This study explores the efficacy of domestic adlay in improving blood sugar and lipids metabolism, cardiovascular function, and weight control in people with high blood pressure, hyperlipidemia, and hyperglycemia. Through two weeks of cooked adlay-rice and white rice by a randomized cross-over design to evaluate the lipid- and glucose-lowering effects of adlay on patient with hyperlipidemia and/or hyperglycemia.

NCT ID: NCT05548933 Recruiting - Hyperlipidemia Clinical Trials

Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia

Start date: September 20, 2022
Phase:
Study type: Observational

This study was a single-center, non-randomized, parallel-group design clinical trial, and each group was assigned a 1:1 ratio with or without hyperlipidemia. Both groups underwent periodontal non-surgical treatment, and blood and gingival crevicular fluid were collected before surgery, 1 month and 3 months after surgery for the detection of MCP-1, IL-8, oxLDL, TNF-α, TG, LDL-C, HDL-C.

NCT ID: NCT05535660 Active, not recruiting - Pregnancy Clinical Trials

Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study

Start date: July 29, 2022
Phase:
Study type: Observational

The purpose of this study is to ascertain lipid profiles during pregnancy, specifically during the 24-28 week gestation and again near term at 36 weeks gestation. The research team are investigating whether lipid profiles can predict adverse maternal and neonatal outcomes.

NCT ID: NCT05393882 Not yet recruiting - Clinical trials for Coronary Artery Disease

Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency

Start date: September 1, 2024
Phase:
Study type: Observational [Patient Registry]

This single-centre cross-sectional study aims to ascertain the impact of dyslipidemia on long-term graft patency after coronary artery bypass grafting (CABG).